Deciphera Pharmaceuticals : Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

– Seventh Approval Worldwide for QINLOCK and First European Approval –
... | October 12, 2021

Related Keywords

Switzerland ,China ,Australia ,Taiwan ,United States ,Canada ,Hong Kong ,Swiss ,Steve Hoerter ,Deciphera Announces Australian Therapeutic Goods Administration Approval ,Linkedin ,Deciphera Pharmaceuticals ,Deciphera Pharmaceuticals Inc ,Nasdaq ,European Union ,Committee For Medicinal Products Human Use ,Swiss Agency For Therapeutic Products Swissmedic ,Deciphera Announces Health Canada Authorization ,European Commission ,Exchange Commission ,Deciphera Press ,Zai Lab Press ,European Medicines Agency ,Clinical Cancer Research ,Swiss Agency ,Therapeutic Products ,Chief Executive Officer ,Medicinal Products ,Human Use ,Private Securities Litigation Reform Act ,Quarterly Report ,Cancer Research ,Press Release ,Fourth Line Gastrointestinal Stromal Tumor ,Deciphera Announces Health Canada ,Lab Press Release ,Advanced Gastrointestinal Stromal Tumors ,Full Approval ,Deciphera Pharmaceutical ,Nc Stock Exchange ,News ,Information ,Seventh ,Approval ,Orldwide ,Or ,Qinlock ,End ,First ,European ,Pproval Dcph Us24344t1016 ,